– UK, London – The Biotech Growth Trust PLC (LON: BIOG) today announced the appointment of Dr. Nicola Shepherd to its Board as an independent non-executive Director effective from 18 January 2021.
“My fellow Directors and I are delighted to welcome Dr. Shepherd to the Board. We are very pleased to have appointed a Director with extensive and relevant expertise both in the UK and internationally,” said Board Chairman, Andrew Joy.
Dr. Shepherd’s appointment will be proposed to shareholders for election at the Annual General Meeting of the Company to be held in July 2021.
About Dr. Nicola Shepherd
Dr Shepherd is the founder and a Director of Bellows Consulting Limited which operates in the biomedical translational sector, providing strategic advice and assisting clients in moving their projects closer to the market.
Previously Dr. Shepherd was a senior member of the Innovations Division at the Wellcome Trust where she was responsible for the establishment, management, and oversight of the Translation Fund, a £30M a year investment into new product development covering therapeutics, vaccines, diagnostics, medical devices and regenerative medicine over a range of clinical indications. Working closely with project teams, from academic, not-for-profit, and commercial organizations, she provided critical guidance and oversight in steering over 50 funded programs from basic research towards or into the clinic.
Dr. Shepherd has also held positions at AstraZeneca in Late-Stage Development and Manufacturing; at Global Prior Art (a patent specialist in intellectual property) based in Boston (US) carrying out competitor analysis, due diligence and prior art searching; and Brown University carrying out post-doctoral research into complex formulations.
Dr. Shepherd is a Member of the CARB-X Advisory Board and a reviewer for Innovate UK.
For more information: https://www.biotechgt.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.